We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Seville, Spain

ICHNO 2026

Session

Radiotherapy and radiobiology
Poster
Daily KV-CBCT–Based Quantification of Setup Errors in Head and Neck Radiotherapy: Implications for PTV Margin Reduction
Himanshi Jain, India
-69
PeLeRad: Randomized multicenter phase II trail of pembrolizumab & lenvatinib after def. RCTx of LA PD-L1 pos. H&N SCC: results of an interim analysis.
Klaus-Henning Kahl, Germany
-143
Towards Proactive Intervention in Radiotherapy: Predicting Acute Radiation Dermatitis Progression from Clinical Images
Luo Huanli, China
-156
Regional control in the pN+ neck with a post-operative de-escalated radiotherapy dose prescription of 50 Gy.
Fréderic Duprez, Belgium
-181
ACCELERATED HYPOFRACTIONATED Vs STANDARD HYPOFRACTIONATED PALLIATIVE RADIOTHERAPY WITH CONCURRENT CHEMOTHERAPY IN LOCALLY ADVANCED HEAD & NECK  CANCER
Suman Bhasker, India
-198
Critical appraisal of hybrid dynamic volumetric modulated arc therapy for the re-irradiation of head and neck cancer patients
Sushil Beriwal, USA
-206
“Maximizing Efficacy, Minimizing Hospital Days:Multicentre Bangladeshi Experience of Weekly Paclitaxel + Carboplatin Concurrent with VMAT in LA-HNSCC”
Md Abdul Mannan, Bangladesh
-215
Patterns of Recurrence After Definitive Chemoradiotherapy in Head and Neck Cancer: Relationship Between Recurrent GTV and Isodose Lines
Ozlem Ozkaya Akagunduz, Turkey
-217
Multiomic Machine Learning Toxicity Modeling for Prediction of Multiple Late Toxicity Outcomes in Head and Neck Cancer Treated with Chemoradiotherapy
Sevda Yener, Turkey
-234
The use of combination palliative radiotherapy and single agent immunotherapy for the management of head and neck squamous carcinoma (HNSCC) in the UK
Naomi Cole, United Kingdom
-236
Contralateral neck relapse rate following definitive unilateral versus bilateral radiotherapy for oropharyngeal squamous cell carcinoma (OPSCC)
Christopher Roberts, United Kingdom
-244
Dose-Dependent Effects of Radiotherapy on Body Composition, Nutritional Status, and Clinical Symptoms in Head and Neck Cancer
Ozlem Ozkaya Akagunduz, Turkey
-254
Voice outcomes, toxicity, and carotid dose reduction with intensity modulated radiotherapy in early glottic cancer: an institutional experience
Anuj Kumar S, India
-273
The AddORN Project: Spatial relationships between dental extractions, maximum mandibular dose and osteoradionecrosis.
Sarah Hargreaves, United Kingdom
-307
Bridging Precision and Access: Challenge of Adaptive Radiotherapy in Head and Neck Oncology In low- and middle-income countries
Cyrine Mokrani, Tunisia
-313
Hippocampal Sparing in Head and Neck Cancer Radiotherapy: Towards a New Standard of Care
Palak Sharma, Ireland
-347
The value of online adaptive radiotherapy for head and neck cancer
Jeppe Friborg, Denmark
-391
impact of second primary cancers on radiotherapy of newly diagnosed head and neck tumors
Annelies Maes, Belgium
-398
Clinical implications of re-irradiation in head and neck cancer and the usefulness of an explainable logistic regression model
Pedro Romero Pareja, Spain
-403
Key Factors Affecting Outcomes in SABR for Head and Neck Tumours Using a Novel Rigid Head Cradle with Vacuum Anchoring Interface
Santiago Velázquez Miranda, Spain
-419
Exclusive High Dose Rate (HDR) Interstitial Brachytherapy for lip squamous cell carcinoma (SCC): regional control and prognostic factors.
Marc Juárez Lozano, Spain
-432
Stereotactic body radiotherapy (SBRT) in oligometastatic and oligoprogressive head and neck cancer: a preliminary single-centre series
Fernando García Luque, Spain
-450
Patterns and Predictors of Dysphagia After Definitive IMRT for Oropharyngeal Squamous Cell Carcinoma
Fernando García Luque, Spain
-461
PERIOPERATIVE HIGH DOSE RATE BRACHYTHERAPY (PHDRB) IN RECURRENT HEAD AND NECK CANCER: AN OPTIMAL OPTION FOR RE-IRRADIATION?
Marc Juárez Lozano, Spain
-477
Stereotactic radiotherapy in the treatment of adenoid cystic carcinoma in the oligometastatic disease stage.
Marek Kentnowski, Poland
-503